SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry

Affiliations


Abstract

Objective: While COVID-19 vaccination prevents severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analysed the clinical characteristics of patients with rheumatic disease who developed breakthrough COVID-19 after vaccination against SARS-CoV-2.

Methods: We included people partially or fully vaccinated against SARS-CoV-2 who developed COVID-19 between 5 January and 30 September 2021 and were reported to the Global Rheumatology Alliance registry. Breakthrough infections were defined as occurring ≥14 days after completion of the vaccination series, specifically 14 days after the second dose in a two-dose series or 14 days after a single-dose vaccine. We analysed patients' demographic and clinical characteristics and COVID-19 symptoms and outcomes.

Results: SARS-CoV-2 infection was reported in 197 partially or fully vaccinated people with rheumatic disease (mean age 54 years, 77% female, 56% white). The majority (n=140/197, 71%) received messenger RNA vaccines. Among the fully vaccinated (n=87), infection occurred a mean of 112 (±60) days after the second vaccine dose. Among those fully vaccinated and hospitalised (n=22, age range 36-83 years), nine had used B cell-depleting therapy (BCDT), with six as monotherapy, at the time of vaccination. Three were on mycophenolate. The majority (n=14/22, 64%) were not taking systemic glucocorticoids. Eight patients had pre-existing lung disease and five patients died.

Conclusion: More than half of fully vaccinated individuals with breakthrough infections requiring hospitalisation were on BCDT or mycophenolate. Further risk mitigation strategies are likely needed to protect this selected high-risk population.

Keywords: COVID-19; antirheumatic agents; vaccination.

Conflict of interest statement

Competing interests: KLH reports she has received non-personal speaker’s fees from AbbVie and grant income from BMS, UCB and Pfizer, all unrelated to this manuscript; KLH is supported by the NIHR Manchester Biomedical Research Centre. LG reports personal consultant fees from AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis and UCB, and grants from Amgen, Lilly, Janssen, Pfizer, Sandoz, Sanofi and Galapagos, all unrelated to this manuscript. AS reports research grants from a consortium of 14 companies (among them AbbVie, BMS, Celltrion, Fresenius Kabi, Gilead/Galapagos, Lilly, Mylan/Viatris, Hexal, MSD, Pfizer, Roche, Samsung, Sanofi-Aventis and UCB) supporting the German RABBIT register and personal fees from lectures for AbbVie, MSD, Roche, BMS, Lilly and Pfizer, all unrelated to this manuscript. LC has not received fees or personal grants from any laboratory, but her institute works by contract for laboratories among other institutions, such as AbbVie Spain, Eisai, Gebro Pharma, Merck Sharp & Dohme España, Novartis Farmaceutica, Pfizer, Roche Farma, Sanofi-Aventis, Astellas Pharma, Actelion Pharmaceuticals España, Grünenthal and UCB Pharma. EF-M reports personal consultant fees from Boehringer Ingelheim Portugal and that LPCDR received support for specific activities: grants from AbbVie, Novartis, Janssen-Cilag, Lilly Portugal, Sanofi, Grünenthal, MSD, Celgene, Medac, Pharmakern and GAfPA; grants and non-financial support from Pfizer; and non-financial support from Grünenthal, outside the submitted work. IB reports personal consultant fees from AbbVie, Novartis, Pfizer and Janssen, all unrelated to this manuscript. JZ reports speaker fees from AbbVie, Novartis and Janssen/Johnson & Johnson, all unrelated to this manuscript. GR-C reports personal consultant fees from Eli Lilly and Novartis, all unrelated to this manuscript. JS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers: R01 AR077607, P30 AR070253 and P30 AR072577), and the R Bruce and Joan M Mickey Research Scholar Fund. JS has received research support from Amgen and Bristol Myers Squibb and performed consultancy for Bristol Myers Squibb, Gilead, Inova, Janssen and Optum, unrelated to this work. LW receives speaker’s bureau fees from Aurinia Pharma, unrelated to this manuscript. SB reports no competing interests related to this work. He reports non-branded consulting fees for AbbVie, Horizon and Novartis (all <$10 000). MGM has no competing interests related to this work. She serves as a patient consultant for BMS, BI JNJ and Aurinia (all <$10 000). RG reports no competing interests related to this work. Outside of this work she reports personal and/or speaking fees from AbbVie, Janssen, Novartis, Pfizer and Cornerstones and travel assistance from Pfizer (all <$10 000). JH reports no competing interests related to this work. He is supported by grants from the Rheumatology Research Foundation and has salary support from the Childhood Arthritis and Rheumatology Research Alliance. He has performed consulting for Novartis, Sobi and Biogen, all unrelated to this work (<$10 000). ESi reports non-financial support from Canadian Arthritis Patient Alliance, outside the submitted work. PS reports personal fees from the American College of Rheumatology/Wiley Publishing, outside the submitted work. ZW reports grant support from Bristol Myers Squibb and Principia/Sanofi and performed consultancy for Viela Bio and MedPace, outside the submitted work. His work is supported by grants from the National Institutes of Health. PMM has received consulting/speaker’s fees from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this study. PMM is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC). PCR reports no competing interests related to this work. Outside of this work PCR reports personal fees from AbbVie, Atom Bioscience, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Kukdong, Novartis, UCB, Roche and Pfizer; meeting attendance support from BMS, Pfizer and UCB; and grant funding from Janssen, Novartis, Pfizer and UCB Pharma (all <$10 000). JY reports no competing interests related to this work. Her work is supported by grants from the National Institutes of Health (K24 AR074534 and P30 AR070155). Outside of this work, she has received research grants or performed consulting for Gilead, BMS Foundation, Pfizer, Aurinia and AstraZeneca.


Figures


Similar articles

Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases.

Hasseli R, Richter JG, Hoyer BF, Lorenz HM, Pfeil A, Regierer AC, Schmeiser T, Strangfeld A, Voll RE, Krause A, Reckert S, Gräßler A, Saar P, Kapelle A, Backhaus M, Blank N, Henes J, Osiek S, Knothe A, Hoese G, Brandt-Jürgens J, Maltzahn A, Specker C, Müller-Ladner U, Schulze-Koops H; COVID-19 task force of the German Society of Rheumatology collaborators; COVID19-Rheuma.de collaborators.RMD Open. 2023 Apr;9(2):e002998. doi: 10.1136/rmdopen-2023-002998.PMID: 37068915 Free PMC article.

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.

Md Yusof MY, Arnold J, Saleem B, Vandevelde C, Dass S, Savic S, Vital EM, Emery P.Lancet Rheumatol. 2023 Feb;5(2):e88-e98. doi: 10.1016/S2665-9913(23)00004-8. Epub 2023 Jan 10.PMID: 36712951 Free PMC article.

An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.

Isnardi CA, Schneeberger EE, Kreimer JL, Luna PC, Echeverría C, Roberts K, de la Vega MC, Virasoro BM, Landi M, Quintana R, Exeni MED, Kogan N, Petkovic I, Pereira D, De Los Ángeles Correa M, Zelaya MD, Tissera Y, Elkin MSG, Pisoni CN, Alonso C, Cogo AK, Cosatti MA, García L, Retamozo C, de Los Ángeles Severina M, Nieto RE, Rosemffet M, Mussano E, Bertoli A, Savio VG, Cosentino V, Pons-Estel GJ.Clin Rheumatol. 2022 Oct;41(10):3199-3209. doi: 10.1007/s10067-022-06253-5. Epub 2022 Jun 28.PMID: 35760939 Free PMC article.

Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases.

Paik JJ, Sparks JA, Kim AHJ.Curr Opin Pharmacol. 2022 Aug;65:102243. doi: 10.1016/j.coph.2022.102243. Epub 2022 May 2.PMID: 35636384 Free PMC article. Review.

SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care.

Wang L, Wang W, Xu R, Berger NA.Best Pract Res Clin Haematol. 2022 Sep;35(3):101384. doi: 10.1016/j.beha.2022.101384. Epub 2022 Sep 29.PMID: 36494154 Free PMC article. Review.


Cited by

Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.

Joudeh AI, Lutf AQ, Mahdi S, Tran G.Vaccine. 2023 Jun 13;41(26):3801-3812. doi: 10.1016/j.vaccine.2023.05.048. Epub 2023 May 22.PMID: 37244811 Free PMC article. Review.

Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases.

Hasseli R, Richter JG, Hoyer BF, Lorenz HM, Pfeil A, Regierer AC, Schmeiser T, Strangfeld A, Voll RE, Krause A, Reckert S, Gräßler A, Saar P, Kapelle A, Backhaus M, Blank N, Henes J, Osiek S, Knothe A, Hoese G, Brandt-Jürgens J, Maltzahn A, Specker C, Müller-Ladner U, Schulze-Koops H; COVID-19 task force of the German Society of Rheumatology collaborators; COVID19-Rheuma.de collaborators.RMD Open. 2023 Apr;9(2):e002998. doi: 10.1136/rmdopen-2023-002998.PMID: 37068915 Free PMC article.

Characteristics of COVID-19 vaccinated and unvaccinated patients admitted to Careggi University Hospital, Florence, Italy.

Paggi R, Barbiero A, Manciulli T, Miftode A, Tilli M, Lagi F, Mencarini J, Borchi B, Pozzi M, Bartalesi F, Spinicci M, Martini L, Coppola A, Nozzoli C, Peris A, Bonizzoli M, Pieralli F, Bartoloni A, Zammarchi L.Intern Emerg Med. 2023 Apr;18(3):821-830. doi: 10.1007/s11739-023-03231-w. Epub 2023 Feb 28.PMID: 36853393 Free PMC article.

Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic.

Zaccardelli A, Wallace ZS, Sparks JA.Curr Opin Rheumatol. 2023 May 1;35(3):175-184. doi: 10.1097/BOR.0000000000000930. Epub 2023 Feb 7.PMID: 36752280 Free PMC article. Review.

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.

Md Yusof MY, Arnold J, Saleem B, Vandevelde C, Dass S, Savic S, Vital EM, Emery P.Lancet Rheumatol. 2023 Feb;5(2):e88-e98. doi: 10.1016/S2665-9913(23)00004-8. Epub 2023 Jan 10.PMID: 36712951 Free PMC article.


KMEL References


References

  1.  
    1. Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. . BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect 2021;27:1652–7. 10.1016/j.cmi.2021.06.036 - DOI - PMC - PubMed
  2.  
    1. Bergwerk M, Gonen T, Lustig Y, et al. . Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021;385:1474–84. 10.1056/NEJMoa2109072 - DOI - PMC - PubMed
  3.  
    1. Brown CM, Vostok J, Johnson H, et al. . Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep 2021;70:1059–62. 10.15585/mmwr.mm7031e2 - DOI - PMC - PubMed
  4.  
    1. Deepak P, Kim W, Paley MA, et al. . Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. Ann Intern Med 2021;174:1572–85. 10.7326/M21-1757 - DOI - PMC - PubMed
  5.  
    1. Haberman RH, Herati R, Simon D, et al. . Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis 2021;80:1339–44. 10.1136/annrheumdis-2021-220597 - DOI - PMC - PubMed
  6.  
    1. Kearns P, Siebert S, Willicombe M. Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity – the OCTAVE trial 2021. Lancet 2021.
  7.  
    1. United States food and drug administration. coronavirus (COVID-19) update: FDA Authorizes additional vaccine dose for certain immunocompromised individuals. United States food and drug administration. Available: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19... [Accessed 9 Sep 2021].
  8.  
    1. Israeli Councils For Health . Summary of an urgent meeting on the issue of vaccines against corona for those who have been vaccinated. Israeli councils for health. Available: https://govextra.gov.il/media/30095/meeting-summary-15122020.pdf [Accessed 9 Sep 2021].
  9.  
    1. COVID-19 vaccination programme information for healthcare practitioners. public health England. Available: https://assets.publishing.service.gov.uk/government/uploads/system/uploa... [Accessed 9 Sep 2021].
  10.  
    1. Die wichtigsten Fragen und Antworten Zur Corona-Impfung. services Der BUNDESREGIERUNG. Available: https://www.bundesregierung.de/breg-de/themen/coronavirus/coronavirus-im... [Accessed 9 Sep 2021].
  11.  
    1. Landewé RB, Machado PM, Kroon F, et al. . EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis 2020;79:851–8. 10.1136/annrheumdis-2020-217877 - DOI - PubMed
  12.  
    1. Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021;80:1255–65. 10.1136/annrheumdis-2021-221244 - DOI - PMC - PubMed
  13.  
    1. Liew JW, Bhana S, Costello W, et al. . The COVID-19 global rheumatology alliance: evaluating the rapid design and implementation of an international registry against best practice. Rheumatology 2021;60:353–8. 10.1093/rheumatology/keaa483 - DOI - PMC - PubMed
  14.  
    1. Wallace ZS, Bhana S, Hausmann JS, et al. . The rheumatology community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance. Rheumatology 2020;59:1204–6. 10.1093/rheumatology/keaa191 - DOI - PMC - PubMed
  15.  
    1. Lawson-Tovey S, Hyrich KL, Gossec L. SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021. 10.1136/annrheumdis-2021-221217 - DOI - PubMed
  16.  
    1. Cook C, Patel NJ, D'Silva KM, et al. . Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. Ann Rheum Dis 2022;81:289–91. 10.1136/annrheumdis-2021-221326 - DOI - PMC - PubMed
  17.  
    1. Cdc COVID-19 study shows mRNA vaccines reduce risk of infection by 91 percent for fully vaccinated people, 2021. Available: https://www.cdc.gov/media/releases/2021/p0607-mrna-reduce-risks.html [Accessed 28 Oct 2021].
  18.  
    1. Izadi Z, Brenner EJ, Mahil SK, et al. . Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open 2021;4:e2129639. 10.1001/jamanetworkopen.2021.29639 - DOI - PMC - PubMed
  19.  
    1. Khoury DS, Cromer D, Reynaldi A, et al. . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205–11. 10.1038/s41591-021-01377-8 - DOI - PubMed
  20.  
    1. Moor MB, Suter-Riniker F, Horn MP, et al. . Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol 2021;3:e789–97. 10.1016/S2665-9913(21)00251-4 - DOI - PMC - PubMed
  21.  
    1. Simon D, Tascilar K, Schmidt K, et al. . Humoral and cellular immune responses to SARS-CoV-2 infection and vaccination in autoimmune disease patients with B cell depletion. Arthritis Rheumatol 2022;74:33-37. 10.1002/art.41914 - DOI - PMC - PubMed
  22.  
    1. Mahil SK, Bechman K, Raharja A, et al. . The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol 2021;3:e627–37. 10.1016/S2665-9913(21)00212-5 - DOI - PMC - PubMed
  23.  
    1. Furer V, Eviatar T, Zisman D, et al. . Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 2021;80:1330–8. 10.1136/annrheumdis-2021-220647 - DOI - PMC - PubMed
  24.  
    1. Geisen UM, Berner DK, Tran F, et al. . Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 2021;80:1306–11. 10.1136/annrheumdis-2021-220272 - DOI - PMC - PubMed
  25.  
    1. Izmirly PM, Kim MY, Samanovic M, et al. . Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination. Arthritis Rheumatol 2022;74:284–94. 10.1002/art.41937 - DOI - PMC - PubMed
  26.  
    1. Prendecki M, Clarke C, Edwards H, et al. . Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis 2021;80:1322–9. 10.1136/annrheumdis-2021-220626 - DOI - PMC - PubMed
  27.  
    1. Ruddy JA, Connolly CM, Boyarsky BJ, et al. . High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021;80:1351–2. 10.1136/annrheumdis-2021-220656 - DOI - PMC - PubMed
  28.  
    1. Boyarsky BJ, Ruddy JA, Connolly CM, et al. . Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis 202110.1136/annrheumdis-2021-220289. [Epub ahead of print: 23 Mar 2021]. - DOI - PMC - PubMed
  29.  
    1. Bonelli MM, Mrak D, Perkmann T, et al. . SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis 2021;80:1355–6. 10.1136/annrheumdis-2021-220408 - DOI - PubMed
  30.  
    1. Mrak D, Tobudic S, Koblischke M, et al. . SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis 2021;80:1345–50. 10.1136/annrheumdis-2021-220781 - DOI - PMC - PubMed
  31.  
    1. Westhoff TH, Seibert FS, Anft M, et al. . Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'. Ann Rheum Dis 2021;80:e162. 10.1136/annrheumdis-2021-220756 - DOI - PubMed
  32.  
    1. Hadjadj J, Planas D, Ouedrani A. Immunogenicity of BNT162b2 vaccine against the alpha and delta variants in immunocompromised patients. MedRxiv 2021. 10.1101/2021.08.08.21261766 - DOI - PMC - PubMed
  33.  
    1. Chiang TP-Y, Connolly CM, Ruddy JA. Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021. 10.1136/annrheumdis-2021-221145 - DOI - PMC - PubMed
  34.  
    1. Hall VG, Ferreira VH, Ku T, et al. . Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med Overseas Ed 2021;385:1244–6. 10.1056/NEJMc2111462 - DOI - PMC - PubMed
  35.  
    1. Kamar N, Abravanel F, Marion O, et al. . Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med 2021;385:661–2. 10.1056/NEJMc2108861 - DOI - PMC - PubMed
  36.  
    1. Benotmane I, Gautier G, Perrin P, et al. . Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA 2021. 10.1001/jama.2021.12339. [Epub ahead of print: 23 Jul 2021]. - DOI - PMC - PubMed
  37.  
    1. Longlune N, Nogier MB, Miedougé M, et al. . High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant 2021;36:1704–9. 10.1093/ndt/gfab193 - DOI - PMC - PubMed
  38.  
    1. Espi M, Charmetant X, Barba T. Justification, safety, and efficacy of a third dose of mRNA vaccine in maintenance hemodialysis patients: a prospective observational study. MedRxiv 2021. 10.1101/2021.07.02.21259913 - DOI - PMC - PubMed
  39.  
    1. Albach FN, Burmester GR, Biesen R. Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response. Ann Rheum Dis 2021;80:1361–2. 10.1136/annrheumdis-2021-220834 - DOI - PubMed
  40.  
    1. Baker MC, Mallajosyula V, Davis MM. Effective viral vector SARS-CoV-2 booster vaccination in a patient with rheumatoid arthritis after initial ineffective mRNA vaccine response. Arthritis Rheumatol 2021. 10.1002/art.41978 - DOI - PMC - PubMed
  41.  
    1. Connolly CM, Teles M, Frey S. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series. Ann Rheum Dis 2021;81. 10.1136/annrheumdis-2021-221206 - DOI - PubMed
  42.  
    1. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. . Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody Sotrovimab. N Engl J Med 2021;385:1941–50. 10.1056/NEJMoa2107934 - DOI - PubMed
  43.  
    1. Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19, 2021. Available: https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-lo... [Accessed 23 Jan 2022].
  44.  
    1. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. . Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med 2022;386:509–20. 10.1056/NEJMoa2116044 - DOI - PMC - PubMed
  45.  
    1. Coronavirus (COVID-19) update: FDA Authorizes first oral antiviral for treatment of COVID-19, 2021. Available: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19... [Accessed 23 Jan 2022].
  46.  
    1. Conroy S, Murray EJ. Let the question determine the methods: descriptive epidemiology done right. Br J Cancer 2020;123:1351–2. 10.1038/s41416-020-1019-z - DOI - PMC - PubMed